Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH001 and Tumor-specific T-cell Injection in Advanced Gastric Cancer
NCT07298200Phase 1Recruiting
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PGV002 in gastric cancer (GC) (2 arms). Primary endpoints: Adverse Events at 12 months and Dose Limiting Toxicity at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
PGV002
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07298200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298200.